INSULET CORPORATION (PODD): what the price assumes

In the published model solve dated 2026-Q2, anchored at $145.13, INSULET CORPORATION (PODD) is priced for +19.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/PODD

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 8: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.3% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• At $145.71 the price embeds roughly 22.9% company-wide operating-profit growth per year for about five years. That pace is within what Insulet has recently delivered; the bet is on how long it persists, not whether it is achievable near term.
• Q1 2026 revenue rose about 33.9% to $761.7 million, with Omnipod 5 driving U.S. growth of 28.3% and international growth of 59.4% in constant currency. Type 2 diabetes adoption is the new leg of the story.
• The watch items are a thin asset and earnings-power floor under the price, a voluntary device correction that pulled gross margin down 240 basis points in the quarter, and direct competition from Tandem and Medtronic plus CGM partners that can shift the platform's economics.

Bull Case

The loudest worry on Insulet is that the price already assumes years of fast growth, and that a single-product company is one competitive misstep away from a derating. So start there and ask whether the data backs the fear or undercuts it. The first quarter of 2026 says the growth is, for now, accelerating rather than fading: revenue rose about 33.9% to $761.7 million, ahead of the company's own 25% to 27% constant-currency guide, with operating income of $122.1 million. The implied bet in the price, roughly 22.9% operating-profit growth per year, sits below what the business just delivered. The stretch is duration, not the current rate.

The engine is Omnipod 5, and it is widening rather than maturing. U.S. Omnipod revenue grew 28.3% and international grew 59.4% in constant currency, with management pointing to a surge in customer starts among type 2 diabetes patients, a population far larger than the type 1 base the pod was built for. The 10-K frames the next leg as broadening the platform: the company describes pursuing "appropriate modifications to our Omnipod technology to address the needs and parameters required for drug-delivery opportunities" (FY2025 10-K), and in 2026 it is expanding CGM compatibility across Dexcom and Abbott sensors and tightening the control algorithm. Each integration makes the pod the hub of more patients' diabetes management.

The competitive position is more durable than the single-product framing suggests. Insulet's pod is tubeless and disposable, a different form factor from the tubed pumps that Tandem and Medtronic sell, and its CGM-agnostic strategy turns potential rivals like Dexcom and Abbott into distribution partners. The recurring nature of pod consumption gives the revenue a subscription-like cadence rather than a one-time hardware sale. Against that, the relative-multiple and forward-growth families both support the current price, which means the market is paying for a real, demonstrated growth franchise rather than a story.

Bear Case

Look first at the structure of the bet, not the product. At $145.71 (June 27, 2026) the equity is being asked to grow operating profit roughly 22.9% a year for about five years, and only about 37% of comparable fast-growers have sustained that pace for five years at this level. That is the base-rate problem: the price is in the upper half of the peer multiple range, and the asset-based and earnings-power valuation families both read it as expensive. There is little balance-sheet or current-earnings cushion beneath the quote. Net debt is modest at roughly $0.95 billion against trailing operating income of about $0.51 billion, so leverage is not the fragility; the fragility is that the value is almost entirely forward, and a single year of decelerating starts would compress the multiple hard.

The single-product concentration is the second exposure. Essentially all revenue is Omnipod, so a manufacturing or quality stumble lands directly on the whole company. That risk is not hypothetical: the first quarter carried a voluntary Omnipod 5 medical device correction that added an estimated $11.7 million in warranty cost and helped pull gross margin down 240 basis points to 69.5%. The 10-K is candid that scaling carries operational risk, warning of "higher defect rates, increased waste, product shortage, unanticipated or increased costs, lost revenues, and damage to our reputation" if it fails to scale manufacturing to meet demand (FY2025 10-K). For a company priced on flawless execution, even a contained recall is a reminder of the tail.

The competitive and dependency map is the third. Tandem and Medtronic are pushing their own automated insulin delivery systems, and Insulet's CGM-agnostic strategy is also a CGM dependency: the pod's value proposition leans on Dexcom and Abbott sensors that those companies control and price. The drug-delivery and type 2 expansion that anchor the long runway are still early, with regulatory and partnership steps the filing itself flags as uncertain. If type 2 adoption proves more price-sensitive or slower than the recent quarter implies, the duration assumption baked into the price is the first thing to break.

Valuation

The valuation families split cleanly. Relative-multiple and forward-growth methods reach or exceed the $145.71 price, while asset-based and earnings-power methods land well below it. That pattern is typical of a high-growth medical-device name: the static frames cannot price a franchise that is still scaling, so the support sits in the methods that look forward. A reasonable-growth re-pricing puts a base value near $140 with a band from roughly $96 to $163, so the current price sits close to the base of that range.

Inverting the price into the assumption it embeds, the market is paying about 24 times company-wide operating income, which implies roughly 22.9% operating-profit growth per year for about five years at a 9.4% cost of capital. The sensitivity is steep: each one-point change in the cost of capital moves the implied growth by about 7.5 points, so the read is rate-dependent. Against the company's own history the near-term pace is within range, and the unusual part is duration. Against the base rate of fast-growers, only about 37% sustained this growth for five years, which is the honest framing of the risk.

The conclusion is that the price is reasonable if Omnipod 5's type 2 and international momentum holds, and full if it does not. There is no dividend to anchor a floor, and the asset and earnings-power methods sit below the quote, so the downside support is thin. This is a growth-durability bet, priced as one.

Catalysts

The near-term driver is the cadence of quarterly Omnipod 5 adoption. First-quarter 2026 revenue rose about 33.9% to $761.7 million, beating the company's 25% to 27% constant-currency guide, with U.S. Omnipod up 28.3% and international up 59.4% in constant currency. For the second quarter the company guided Omnipod revenue growth of 21% to 23% and total revenue growth of 20% to 22%, and it continues to expect adjusted EPS to rise more than 25% for the full year. Each print is a check on whether the type 2 diabetes ramp is durable.

Product cadence is the second catalyst. In 2026 Insulet is rolling out algorithm enhancements to Omnipod 5, including a lower 100 mg/dL target glucose option, and broadening CGM compatibility across Dexcom G6 and G7 and Abbott's FreeStyle Libre 2 Plus. Wider sensor support and a sharper control algorithm both expand the addressable base and deepen the platform lock-in. The longer-dated optionality is the drug-delivery work the 10-K describes, which is early and partnership-dependent.

The watch items are the voluntary Omnipod 5 medical device correction that added about $11.7 million of warranty cost in the quarter and weighed on gross margin, and the competitive response from Tandem and Medtronic. Analyst sentiment is constructive, with a Buy-leaning consensus, though targets span a wide range and at least one recent move was a downgrade to Hold on valuation after the strong run. Insulet pays no dividend, so total return rests entirely on growth execution.

Sources:

• https://www.stocktitan.net/sec-filings/PODD/8-k-insulet-corp-reports-material-event-ffb2065e126d.html
• https://www.indexbox.io/blog/insulet-q1-2026-results-strong-revenue-growth-despite-market-concerns/
• https://www.quiverquant.com/news/Insulet+shares+rise+as+investors+focus+on+Omnipod+5+software+upgrade+and+expanded+CGM+compatibility
• https://stockanalysis.com/stocks/podd/forecast/
• https://www.fool.com/coverage/better-buy/2026/06/04/dexcom-vs-insulet-which-diabetes-stock-is-a-better-buy-in-2026/

Peer Cohorts (Per Segment, With Filing Citations)

Omnipod insulin delivery (single operating segment) (reported)

• DXCM (DEXCOM, INC.)
• FY2025 10-K: …new product introductions and other market activities of industry participants. In selling our current CGM systems, we compete directly with the Diabetes Care division of Abbott Laboratories; Medtronic plc's Diabetes Group (which implemented a spinoff of its diabetes business into a separate company called MiniMed);…
• FY2025 10-K: …diabetes research are continually seeking ways to prevent, cure or improve treatment of diabetes. Therefore, our products may be rendered obsolete by technological breakthroughs in diabetes monitoring, treatment, prevention or cure. In selling our G6, G7, G7 15 Day, Dexcom One and Dexcom ONE+, we compete directly…
• TNDM (Tandem Diabetes Care, Inc.)
• FY2025 10-K: …support activities in 2026, starting with the United Kingdom, Austria, and Switzerland, and intend to continue this transition in additional markets across 2026. Sales Concentrations and Significant Customers. A small number of independent distributors in the United States and Canada are responsible for order…
• FY2025 10-K: …a new pump. These enhancements generally include new developments in our AID technology, CGM integrations and mobile app features. For more than a decade we have offered our customers, their caregivers and healthcare providers a data management application to provide a fast, easy and visual way to display diabetes…
• TMDX (TransMedics Group, Inc.)
• FY2025 10-K: …performance obligation. The Company recognizes revenue from the single, combined performance obligation only once the OCS Console has arrived at the customer site and the training and equipment set-up have been completed by the Company. Customer orders may include the loan of an OCS Console as well as OCS disposable…
• FY2025 10-K: …OCS Console, whether sold or loaned to the customer. We evaluate each promise within a multiple-performance obligation arrangement to determine whether it represents a distinct performance obligation. The primary performance obligations in our customer arrangements from which we derive revenue are the OCS Perfusion…
• PEN (Penumbra, Inc)
• FY2025 10-K: …We implemented several proprietary design innovations to enable the coil to maintain shape while achieving biomechanically stable occlusion. Given the size and handling of Penumbra Coil 400, it is able to achieve higher packing density with fewer coils compared to competitive coiling systems. Penumbra SMART COIL is a…
• FY2025 10-K: …and embolization and access. We sell our products through purchase orders, and we do not have long term purchase commitments from our customers. Revenue from product sales is recognized either on the date of shipment or the date of receipt by the customer, but is deferred for certain transactions when control has not…
• IRTC (iRhythm Holdings, Inc.)
• FY2025 10-K: …of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable…
• FY2025 10-K: …for the iRhythm ACM Systems, new therapeutic discoveries, development of an analytical engine for ambulatory consumers, other medical data and payor and provider decision support, and the potential for more complete system integration with large health systems. We have supported clinical studies conducted by leading…
• ATRC (AtriCure, Inc.)
• FY2025 10-K: …procedures. In open-heart procedures, the physician performs heart surgery for other conditions, and our products are used in conjunction with (or "concomitant" to) such a procedure. Minimally invasive procedures are performed on a standalone basis, and often include multi-disciplinary or "hybrid" approaches,…
• FY2025 10-K: …with an endocardial ablation catheter. Our EPi-Sense ST Guided Coagulation System was approved via PMA supplement in late 2022. Hybrid AF Therapy is the only FDA-approved minimally invasive procedure to treat patients with long-standing persistent Afib and represents a proven option for patients with this advanced…
• MMSI (MERIT MEDICAL SYSTEMS INC)
• FY2025 10-K: …as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding…
• FY2025 10-K: …market medical products for interventional and diagnostic procedures. For financial reporting purposes, we report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural…
• TFX (TELEFLEX INCORPORATED)
• FY2025 10-K: …31, 2025, we recognized post-acquisition revenue and a pre-tax operating loss related to the VI Business of $ 202.4 million and $ 90.8 million, respectively. The pre-tax operating loss primarily reflects the impact of the amortization of the step-up in carrying value of inventory and intangible assets recognized in…
• FY2025 10-K: …continuing reduced demand for bariatric surgery procedures in future periods, driven by the growing adoption of GLP-1 products. We performed a recoverability test, utilizing an updated long-term forecast reflecting higher uncertainty of revenue growth in future periods compared to previous estimates, and concluded…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.